Company profile: Xaira
1.1 - Company Overview
Company description
- Provider of AI-driven drug discovery and therapeutic product development across multiple modalities. Offers R&D of AI methods for biological discovery, molecule and protein design, and clinical development, powered by a data platform that generates, integrates, and learns from multidimensional datasets to advance disease understanding and create medicines targeting resistant molecular targets.
Products and services
- AI Drug Discovery: Engineers drugs using AI-driven technology to develop therapeutics, applying artificial intelligence to discovery processes for disease-focused medicine creation
- Data Platform: Delivers a multidimensional platform that generates, integrates, and learns from multidimensional data sets to deepen disease understanding
- Protein Design: Architects new proteins using AI-guided approaches to create medicines targeting resistant molecular targets
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xaira
360 Vantage
HQ: United States
Website
- Description: Provider of cloud-based CRM, sales force automation, and closed-loop marketing systems for the life sciences industry, offering 360 CRM, 360 CLM, compliance and e-learning solutions, along with a full suite of professional and managed services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 360 Vantage company profile →
Genuity Science
HQ: United States
Website
- Description: Provider of clinco-omics data analysis solutions and genomic sequence data for researchers, with a platform for study design, sequencing, storage, interpretation, secondary analysis, and scalable analytics. Offers disease-specific clinical omics datasets (CNS, cardiometabolic, inflammatory), powered datasets, deeply phenotyped whole genomes, longitudinal data, and population-scale expertise applying deep learning to improve patient health using the human genome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genuity Science company profile →
Longboat
HQ: Ireland
Website
- Description: Provider of well-designed, practical technology solutions that address investigator site engagement and protocol compliance challenges in global clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Longboat company profile →
Deep Origin
HQ: United States
Website
- Description: Provider of a cloud-based life sciences R&D platform with customizable bioinformatics and biosimulation workstations, pre-installed tools, and NVIDIA GPUs; a molecular simulation and AI toolkit for compound screening, protein motion prediction, and ADMET; scalable, shareable ComputeBenches (up to 192 vCPUs); expert-curated software blueprints; and team collaboration via Organizations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Deep Origin company profile →
Smart-Trial
HQ: Denmark
Website
- Description: Provider of a global SaaS platform for clinical data management for medical devices, designed to collect and manage data throughout the medical device lifecycle, helping manufacturers illustrate device quality and safety by improving data collection and management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Smart-Trial company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xaira
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xaira
2.2 - Growth funds investing in similar companies to Xaira
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xaira
4.2 - Public trading comparable groups for Xaira
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →